Chlorambucil in indolent mantle cell lymphoma - Just another old drug for a new disease?

Leukemia and Lymphoma

Volumn 52, Issue 3, 2011, Pages 351-352

  Dreyling, Martin ^a   Polliack, Aaron ^b   Tadmor, Tamar ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

chlorambucil (Leukeran); indolent lymphomas; Mantle cell lymphoma

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; MITOXANTRONE; PHENYLACETIC ACID; PREDNISONE; RITUXIMAB;

AUTOTRANSPLANTATION; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOLOGY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; RISK FACTOR; TREATMENT RESPONSE; URINARY EXCRETION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; CHLORAMBUCIL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG REPOSITIONING; DRUG THERAPY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; PREDNISONE; SURVIVAL ANALYSIS;

EID: 79951692444     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.552140     Document Type: Note

References (14)

1. Dreyling M, Hiddemann W: Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book Hematology 2009: 542-554.
2. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010 Feb 15;70(4):1408-18.
3. Harris NH, Jaffe ES, Diebold, J et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. JCO December 1, 1999 vol. 17 no. 12 3835-38.
4. Lennert K, Mohri N, Stein H, Kaiserling E. The Histopathology of Malignant Lymphoma. Br J Hematol. 1975;31(s1);193-203.
5. Galton DA, Szur L, Dacie JV. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Br J Hematol; 1961;7;73-98.
6. Knospe WH, Virgil L, Huguley CM. Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer. 1974;33:555-562
7. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326-1331
8. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376:1164-1174.
9. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009 Oct 15;114:3382-91.
10. Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Hematol. 2003;123:271-277 (Pubitemid 37305061)
11. Sanchanas S, Pangalis GA, Vassilakopoulos TP, et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leukemia Lymp 2011;52:387-393.
12. Olivier Hermine, Eva Hoster, Jan Walewski, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood, Volume 116 ;21; #110.
13. Martin P, Chadburn A, Christos P, et al. outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27: 1209-1213.
14. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL ASH 2009, #405.